Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study.

Background: Amantadine has been proposed as a treatment for COVID-19 because it shows anti-SARS-CoV-2 activity in vitro. However, to date, no controlled study has assessed the safety and efficacy of amantadine in COVID-19.

Research Question: Whether amantadine is effective and safe among patients with different COVID-19 severity classifications.

Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results.

Introduction: This phase III trial was conducted in non-small cell lung cancer patients with locally advanced stage II B (only T3N0) III A and III B (only T4 N0). Primary endpoint was 2-year survival; secondary were toxicity, disease-free survival, and overall survival.

Methods: After three cycles of vinorelbine (N) 25 mg/m2 on days 1 and 5, ifosfamide/mesna (I) 3 g/m2 on day 1, cisplatin (P) (NIP), patients were treated by surgery and within 45 days were randomized to two additional cycles of NIP versus observation.

Exercise-induced ventricular tachycardia associated with coronary arteriovenous fistula and correction by transcatheter coil embolization.

Exercise-induced ventricular tachycardia is a well-described arrhythmia most commonly associated with atherosclerotic coronary artery disease. The case reported here presents its association with a coronary arteriovenous fistula, which has not been previously reported in the literature.

[Occurrence of antituberculous antibodies in patients with lung tuberculosis and other inflammatory states of the respiratory system].

In this study an indirect immunofluorescence method was applied. Determinations regarded the level of anti-H37Rv antibodies in patients with bacteriologically confirmed lung tuberculosis and in a control group consisting of healthy volunteers. Antibody levels were significantly higher in sick patients.